Skip to content
  • Home
  • Submission
    • WMO applicable
    • Non WMO research
    • Approval Board of Directors UMCG
    • Biobank and/or databank
  • Documents
  • Topics
    • Adverse Events (SAEs, SUSARs, SADEs, etc.)
  • Contact & Info
    • Composition METc UMCG
    • METc UMCG meetings
    • METc UMCG Fee
    • More practical information
  • FAQ
  • News
    • Meeting dates 2023
  • English
    • Dutch
Menu
  • Home
  • Submission
    • WMO applicable
    • Non WMO research
    • Approval Board of Directors UMCG
    • Biobank and/or databank
  • Documents
  • Topics
    • Adverse Events (SAEs, SUSARs, SADEs, etc.)
  • Contact & Info
    • Composition METc UMCG
    • METc UMCG meetings
    • METc UMCG Fee
    • More practical information
  • FAQ
  • News
    • Meeting dates 2023
  • English
    • Dutch
Search
Close this search box.

Best Practise for multinational transition trials

A timely transition to CTR of investigator initiated trials with medicinal product is important. This can only be done thru the online submission portal CTIS. Clinical trials with medicinal products that have at least one active site on the 30th of January 2025 must be transitioned to CTR. Trials that are not yet approved according to CTR loose their previous approval and will be terminated per 31st January 2025.

Recently, the CTCG (Clinical Trial Coordination Group) has published a Best Practise document for sponsors which describes how to prepare for a multinational trial with different versions of the research protocol.

This document can be found here: Best Practice Guide.

There’s an accompanying Cover letter template. That document can be found here: cover letter template.

Print or export to pdf
  • Home
  • Submission
  • Topics
  • FAQ
  • Documents
  • Information & contact
  • Home
  • Submission
  • Topics
  • FAQ
  • Documents
  • Information & contact

POWERED BY Wild Sea 2020